Differential effects of milnacipran, fluvoxamine and paroxetine for inhibited and agitated depression.
Morishita
Shigeru
S
Depression Prevent Medical Center, Kyoto Jujo Hospital, 32 Kisshoinhattandacho, Minaki-Ku, Kyoto 601-8325, Japan. s.morishita31@r9.dion.ne.jp
Arita
Seizaburo
S
D015331:Cohort Studies; D003521:Cyclopropanes / Q000627:therapeutic use*; D003863:Depression / Q000150:complications* / Q000188:drug therapy*; D004334:Drug Administration Schedule; D016666:Fluvoxamine / Q000627:therapeutic use*; D006801:Humans; D000078764:Milnacipran; D017374:Paroxetine / Q000627:therapeutic use*; D011595:Psychomotor Agitation / Q000150:complications* / Q000188:drug therapy*; D012189:Retrospective Studies; D017367:Selective Serotonin Reuptake Inhibitors / Q000627:therapeutic use*; D011795:Surveys and Questionnaires
D003521:Cyclopropanes; D016666:Fluvoxamine; D000078764:Milnacipran; D017374:Paroxetine; D017367:Selective Serotonin Reuptake Inhibitors